3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
2
NETWORK
2
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thoracic Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Interventions
nilotinib
50
Imatinib Mesylate
48
Dasatinib
25
bosutinib
18
asciminib
17
ponatinib
10
Homoharringtonine
5
Cytarabine
4
olverembatinib
3
Interferon-alpha
3
Decitabine
3
tozasertib
2
peginterferon alfa-2a
2
flumatinib
2
fludarabine phosphate
2
ON 01910
2
Mycophenolic Acid
2
Melphalan
2
Interferon alpha-2
2
Filgrastim
2
Cyclophosphamide
2
Bone Marrow Transplantation
2
BID protein, human
2
Azacitidine
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
vosaroxin
1
troxacitabine
1
triciribine
1
terameprocol
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Patient Reported Outcome Measures
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled